Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
The differential diagnosis between atypical leiomyoma and leiomyosarcoma may be hard based on morphological criterion at times. It would be helpful to find out biomarkers that can be used to distinguish them. The aim of the study was to investigate the diagnostic value of progesterone receptor (PR), p16, p53 and pHH3 expression in a series of uterine smooth muscle tumors. Immunohistochemical expression of PR, p16, p53 and pHH3 was investigated on 32 atypical leiomyomas, 15 leiomyosarcomas and 15 usual leomyomas. The difference in expression was compared between atypical leiomyoma and other groups. The expression of PR, p16, and pHH3 was found significantly different between atypical leiomyomas and leiomyosarcomas, but lack of significant difference between atypical leiomyomas and usual leiomyomas. There was no significant difference with regard to p53 distribution among these uterine smooth muscle tumors. High p16, pHH3 expression and low PR expression preferred the diagnosis of leiomyosarcoma. The panel of antibodies used in this study is a useful complementary analysis in the assessment of problematic uterine smooth muscle tumors.
Department of Surgical Pathology, The Affiliated Women's Hospital, School of Medicine, Zhejiang University Zhejiang Province 310006, P. R. China.
Yun
Y
Liang
Department of Surgical Pathology, The Affiliated Women's Hospital, School of Medicine, Zhejiang University Zhejiang Province 310006, P. R. China.
Xiaofei
X
Zhang
Department of Surgical Pathology, The Affiliated Women's Hospital, School of Medicine, Zhejiang University Zhejiang Province 310006, P. R. China.
Xiaoduan
X
Chen
Department of Obstetrics and Gynecology, The Affiliated Women's Hospital, School of Medicine, Zhejiang University Zhejiang Province 310006, P. R. China.
Weiguo
W
Lü
D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D019941:Cyclin-Dependent Kinase Inhibitor p16; D003937:Diagnosis, Differential; D005260:Female; D006657:Histones / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D007890:Leiomyosarcoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D010766:Phosphorylation; D011237:Predictive Value of Tests; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D014594:Uterine Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy
D014408:Biomarkers, Tumor; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D006657:Histones; D009363:Neoplasm Proteins; D011980:Receptors, Progesterone; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
Atypical leiomyoma; PR; immunohistochemistry; p16; p53; pHH3